Trial Profile
A phase III randomized controlled study of adjuvant chemoradiotherapy plus or without anrotenib after primary treatment of locally advanced tongue cancer
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jun 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Squamous cell cancer; Tongue cancer
- Focus Therapeutic Use
- 22 Jun 2020 New trial record